Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005817 · ClinicalTrials.gov registry record · Phase 2
Rebeccamycin Analogue in Treating Women With Stage IIIB or Stage IV Breast Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
NCT00005817: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00005817 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 42 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00005817, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
Study Summary
Randomized phase II trial to compare the effectiveness of two regimens of rebeccamycin analogue in treating women who have stage IIIB or stage IV breast cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. The best way to give rebeccamycin analog in breast cancer patients is not yet known
Interventions
- OTHER laboratory biomarker analysis
- DRUG becatecarin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2000-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00005817
The ClinicalTrials.gov registry entry for NCT00005817 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which laboratory biomarker analysis is the first listed.
NCT00005817 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00005817 about?
NCT00005817 is a clinical study titled "Rebeccamycin Analogue in Treating Women With Stage IIIB or Stage IV Breast Cancer". Randomized phase II trial to compare the effectiveness of two regimens of rebeccamycin analogue in treating women who have stage IIIB or stage IV breast cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. The best way to give rebeccamy...
What is the current status of trial NCT00005817?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2000-03.
What interventions are being tested in trial NCT00005817?
The interventions under investigation include: laboratory biomarker analysis (OTHER), becatecarin (DRUG).
Who is sponsoring clinical trial NCT00005817?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.